Clinical Trials Logo

HER-2 Positive Gastric Cancer clinical trials

View clinical trials related to HER-2 Positive Gastric Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03588533 Recruiting - Metastatic Cancer Clinical Trials

Herzuma-capecitabine/Cisplatin for Gastric Cancer

HERZUMA-GC
Start date: June 10, 2018
Phase: Phase 2
Study type: Interventional

Stomach cancer is the fifth largest cancer in the world. Despite many combinations of studies, metastatic stomach cancer shows a median survival period of 10 to 12 months. According to a report in Korea in 2010, 17 % of cancer patients had over-expression of human epidemiology growth factor receptor 2 (HER-2). And Using of Trastuzumab reported better results.Herzuma® is the Trastuzumab biosimilar (Biosimilar) cloned antibody. In this study, the investigators want to prospectively analyze the effects and side effects of Herzuma® in gastric or gastroesophageal adenocarcinoma.

NCT ID: NCT02380131 Recruiting - Liver Metastasis Clinical Trials

Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis

Start date: February 2013
Phase: Phase 4
Study type: Interventional

Stage Iļ¼špreoperative therapy - Capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis; Stage II: Perioperative therapy - Perioperative Capecitabine plus oxaliplatin with herceptin is superior to adjuvant Capecitabine plus oxaliplatin alone for patients with potentially resectable HER-2 positive gastric cancer with liver metastasis;